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Variants of unknown signiﬁcance
A B S T R A C T
Marfan syndrome (MFS) is a multisystem autosomal dominant heritable disorder and, although there are
over 1700 mutations that have been identiﬁed in the ﬁbrillin-1 (FBN1) gene associated with it, there are
many variants that remain unknown. Here we report two family cases of MFS with two new undescribed
variations (C914S and H2426C) in FBN1 gene. Both variations produce alterations in the structural
conformation of the protein resulting in pathogenic events in these patients. Finally, this case report
includes both pathogenic mutations that have also been clinically and genetically conﬁrmed to result in
MFS. This clinical, genetic, and in silico analysis of potentially harmful variations in unrelated MFS
patients provides additional evidence for the suggested causative role of the mutations c.2740T > A
(C914S), c.7276_7278delCAT (p.H2426C) in FBN1 gene in MFS.
<Learning objective: New previously undescribed mutations in ﬁbrillin-1 (FBN1) gene related to
Marfan syndrome (MFS) have been conﬁrmed by genetic, bioinformatics, and clinical studies. It is well
known that MFS is caused by mutations in FBN1 gene; however many of them remain unknown. These
data could be relevant in the screening of these patients offering a different follow-up by considering
these and other genetic mutations. These types of mutations should be considered in differential
diagnosis.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Marfan syndrome (MFS; MIM#154700) is a multisystem
autosomal dominant heritable disorder mainly caused by muta-
tions in the ﬁbrillin-1 gene (FBN1) at 15q21.1 [1]. Although there
are over 1700 mutations that have been identiﬁed in the FBN1 gene
associated with MFS, other mutations have not yet been described
[2]. Fibrillins are an integral component of the extracellular matrix
of connective tissue, and therefore mutations in the genes
encoding them are likely to cause disruption of the connective* Corresponding author at: Laboratorio de Identiﬁcacio´n Gene´tica, Departamento
de Medicina Legal y Toxicologı´a, Facultad de Medicina, Universidad de Granada,
Avda. de Madrid, 11.18071, Granada, Spain. Tel.: +34 958249950;
fax: +34 958246107.
E-mail address: mjesusac@ugr.es (M.J. Alvarez-Cubero).
http://dx.doi.org/10.1016/j.jccase.2014.08.007
1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightstissue [3]. Although there are over 1000 FBN1 mutations associated




A 53-year-old Caucasian male with symptomatic signs of MFS
was analyzed by a specialist. Physical examination showed no
alterations in head or neck, and rhythmic noise without murmurs.
Other complementary examinations dismissed aortic dilated root.
Clinical analysis proved that an aortic thoracic aneurysm is
produced by smoking (the patient smokes around 20 cigars per
day). A screening computed tomography (CT) angiography and
genetic analysis in main genes of MFS (FBN1 and TGFR2) were
requested by the doctor. Other data were unremarkable. reserved.
Table 1 Undescribed mutations in patients of Marfan syndrome.
Nucleotide Protein Pathology Gene Location Effect
c.2740T > A p.C914S MFS FBN1 Exon 24 Missense
c.7276_7278delCAT p.H2426C MFS FBN1 Exon 59 Missense
MFS, Marfan syndrome.
The data were established by comparison with the reference sequence NM_000138.4 in FBN1 gene.
Table 2 Program details of in silico analysis.
Program name URL Prediction
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/ Based on a decision tree that combines a number of protein structural attributes with a
prebuilt sequence alignment, generally including only mammalian sequences.
SNPs&GO http://snps-and-go.biocomp.unibo.it/snps-and-go/ The prediction of human disease-related single point protein mutations predicting
whether a mutation at the protein level is or is not disease-related
MutPred http://mutpred.mutdb.org/ Classiﬁcation of an amino acid substitution as disease-associated or neutral in human.
In addition, it predicts molecular cause of disease.
SIFT http://sift.jcvi.org/ Whether an amino acid substitution affects protein function, its prediction is based on the
degree of conservation of amino acid residues in sequence alignments derived from
closely related sequences.
AlignGVGD http://agvgd.iarc.fr/agvgd_input.php Combines an alignment with amino acid physicochemical characteristics to calculate the
range of variation present at each position in the alignment (GV) and the distance of
missense substitutions from that range of variation (GD).
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a previously undescribed mutation in the main databases such
as http://www.hgmd.cf.ac.uk/ac/search.php and Genecards-
Uniprot. p.His2426Cys (p.H2426C) mutation (Table 1) produces
a deletion of three nucleotides in the coding region. This
mutation produces a lack of histidine amino acid which affects
the domain of epidermal growth factor (EGF)-like protein
41-calcium-binding. Furthermore, according to clinical refer-
ences these changes are considered to produce clinical altera-
tions due to the effects on a highly conservative region of the
protein. In silico analysis could not be performed due to the type
of this variation to conﬁrm the pathogenetic effect of this
change (Table 2). However, we have performed in silico analysis
in other related genes (TGFBR1/2 genes) to eliminate the
possibility of this being a mutation in other genes, obtaining
negative results for these genes.
After the genetic analysis, due to the implications of this
variation and the inheritable characteristics of MFS, the same
genetic analyses were performed in his descendents (two
daughters and a son). The 16-year-old son has the mutation and
was also affected by MFS diagnosed by this familial analysis.
c.2740T > A (C914S) variation
A 32-year-old Caucasian male with symptomatic signs of MFS
and several cases of ectopia lentis in his family was analyzed
in FBN1 gene to conﬁrm MFS. This patient had ocular and vascular
(z score 2.67) effects but no systemic effects (score <5). Genetic
analysis described p.Cys914Ser (p.C914S) variation in FBN1
gene. This variation produces a change between amino acids
with different size and change which produces a worse
prognosis. Furthermore, this change alters disulphur bonds and
in consequence the 3D structure of the extracellular protein. In
silico analysis conﬁrmed the pathogenicity of this mutation with
high score of pathogenicity classiﬁcation (99.6% with PolyPhen-2,
9/10 with SNPs&GO, 98% being deleterious in MutPred, and 0 value
in SIFT). Similar to a previous case report, a genetic study was
performed on other relatives and found that there were two
children (5- and 4-year-olds) with the mutation and both affected
by MFS, having ocular effects and aortic z-score of 2.5 and 2.35,
respectively. The mother (59 years) with systemic, ocular, and
skeletal effects and aunt (53 years) were also affected and both
presented the mutation. However, a daughter was absent of the
syndrome and the mutation.Discussion
As can be seen in this analysis, there are many new mutations
discovered by genetic testing. Some of the mutations have been
previously described and their effects are well known; however,
some others reveal missense substitutions that are not easily
classiﬁed as pathogenic or neutral. Actually, it is a real problem to
deﬁne which variants of uncertain clinical signiﬁcance (VUS) are
deleterious/disease causing and which are neutral, and among
other tools, in silico analysis could predict the pathogenicity or not
of an undescribed mutation. Having sequence VUS makes it
difﬁcult to classify the variants into high- or low-risk in patients.
These results prove that in the case of MFS, as well as in many
cancers and other pathologies, the existence of VUS is a common
event and we describe two new variations for MFS that can be
included for the next genetic analysis in this disease.
Most mutations in exons 24–32 of FBN1 gene are predictive of a
severe cardiovascular phenotype even in non-neonatal cases, and
mutations leading to premature truncation codons are under-
represented in this region [4]. Mainly, this region includes the
central longest stretch of Ca2+-binding (cb) EGF repeats, which is
thought to form a rigid rod-like structure that may be important for
microﬁbril assembly, and contains a wide number of genes [4,5].
Previously reported data from patients’ blood of MFS indicate
that intronic variants that alter cysteine residues will have a worst
prognosis due to the fact that they are usually linked to highly
conservative domains and any change in them could lead to a loss
of secondary structure of the protein. Furthermore, most muta-
tions in exons 24–32 of FBN1 gene are predictive of a severe
cardiovascular phenotype even in non-neonatal cases, and that
mutations leading to premature truncation codons are under-
represented in this region [4]. Mainly, this region includes the
central longest stretch of cbEGF repeats, which is thought to form a
rigid rod-like structure that may be important for microﬁbril
assembly [4].
Conclusion
This case report emphasizes the important role and high
diagnostic certainty of genetic tests in MFS identifying potential
mutations of severe and familial cases of MFS in FBN1 gene. These
data in combination with clinical information could offer better
qualities of clinical treatments to the patient and advances in the
detection of this syndrome. Furthermore, these data improve the
F. Cabrera-Bueno et al. / Journal of Cardiology Cases 10 (2014) 235–237 237current mutation database of this syndrome giving clinical
information to VUS in FBN1.
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